TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Carboplatin
  • Cisplatin
  • Triple Negative Breast Neoplasms

abstract

  • Platinum agents are active in mTNBC, especially in patients with germline BRCA1/2 mutations. A measure of tumor DNA repair function may identify patients without mutations who could benefit from platinum therapy agents. Prospective controlled confirmatory trials are warranted.

publication date

  • June 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4451173

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.57.6660

PubMed ID

  • 25847936

Additional Document Info

start page

  • 1902

end page

  • 9

volume

  • 33

number

  • 17